CN1228074C - Chinese traditional medicine for treating immune hypofunction and disfunction - Google Patents
Chinese traditional medicine for treating immune hypofunction and disfunction Download PDFInfo
- Publication number
- CN1228074C CN1228074C CN 03135227 CN03135227A CN1228074C CN 1228074 C CN1228074 C CN 1228074C CN 03135227 CN03135227 CN 03135227 CN 03135227 A CN03135227 A CN 03135227A CN 1228074 C CN1228074 C CN 1228074C
- Authority
- CN
- China
- Prior art keywords
- disfunction
- portions
- edema
- treating
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000006187 pill Substances 0.000 claims abstract description 6
- 241000756943 Codonopsis Species 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 230000001900 immune effect Effects 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 32
- 230000007812 deficiency Effects 0.000 abstract description 11
- 206010018367 Glomerulonephritis chronic Diseases 0.000 abstract description 9
- 235000019789 appetite Nutrition 0.000 abstract description 8
- 230000036528 appetite Effects 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 206010011224 Cough Diseases 0.000 abstract description 2
- 210000003127 knee Anatomy 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 26
- 238000012360 testing method Methods 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 20
- 210000002105 tongue Anatomy 0.000 description 20
- 210000002700 urine Anatomy 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 208000011580 syndromic disease Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 230000036737 immune function Effects 0.000 description 8
- 208000017169 kidney disease Diseases 0.000 description 8
- 230000003907 kidney function Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 241000545442 Radix Species 0.000 description 6
- 208000019790 abdominal distention Diseases 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009592 kidney function test Methods 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000009571 yupingfeng Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicine for treating immune hypofunction and disfunction, which is mainly prepared by refining 10 to 20 portions of astragalus root, 3 to 9 portions of pilose asiabell root, 4 to 12 portions of white atractylodes rhizome, 6 to 18 portions of tuckahoe, 8 to 16 portions of epimedium herb and 5 to 15 portions of glossy privet fruit according to the requirement of each dosage form of preparation. The traditional Chinese medicine for treating immune hypofunction and disfunction has the functions of supplementing the spleen, tonifying the kidney, benefiting vital energy and consolidating the constitution and can be used for treating spleen-kidney vacuity, fatigued body and lack of strength caused insufficiency of right qi, poor appetite, limp aching lumbus and knees, edema and cough with dyspnea or chronic diseases accompanied with cell immune hypofunction and disfunction. The traditional Chinese medicine for treating immune hypofunction and disfunction has obvious functions of enhancing and regulating immune hypofunction or disfunction and has obvious effect on treating qi deficiency and edema (chronic nephritis). The dosage form of the present invention can be a tablet, a granule, a pill, a capsule and oral medicinal liquid.
Description
Affiliated technical field: the invention belongs to Chinese medicine and preparation method thereof, specifically is a kind of immunologic hypofunction or disorderly Chinese medicine for the treatment of.
Background technology: along with immunologic further investigation, in the developing of disease, immunologic function low or disorderlyly more and more cause people's attention regulated immunologic function referred consequence in the treatment of numerous disease.Immune dysfunction disease incidence height clinically, the immunomodulator demand is big.A large amount of studies show that Chinese medicine has better curative effect to many immune diseases.Many Chinese medicines and compound recipe can pass through number of ways, the immunologic function that enhancing body active immunity power, recovery body are weakened.Some Chinese medicines contain two kinds of compositions of mutual antagonism, act on paired regulation and control substance in the body, and low immunologic function was improved, and too high immunologic function is reduced, and show as dual regulation.Set upright the stability that the rule of treatment can the enhancing human body immunity function, can suppress the caused pathological change of immunoreation again.But significantly the Chinese patent medicine of raise immunity is actually rare at present, and especially when promoting immunity, the Chinese patent medicine with dual regulation is not seen as yet.
The objective of the invention is at above-mentioned condition, make full use of Chinese medicine and adjusting fuselage state.Transfer the characteristics of inherent resistance against diseases aspect, utilize the Chinese medicine strengthening the body resistance, unique advantages such as two-ways regulation, for people provide a kind of promoting that immunity is main effect, and treatment immunologic hypofunction or disorderly Chinese medicine that can the two-ways regulation immunologic derangement.
The objective of the invention is to realize by following technical proposals.
Summary of the invention: the present invention treats immunologic hypofunction or disorderly Chinese medicine, main raw material by following formulation by weight: Radix Astragali 10-20 part, Radix Codonopsis 3-9 part, Poria 6-18 part, Rhizoma Atractylodis Macrocephalae 4-12 part are refined into tablet, granule, pill, capsule or oral liquid by each dosage formulation requirement.
In the above-mentioned raw materials.Can also add Fructus Ligustri Lucidi 5-15 part and/or Herba Epimedii 8-16 part.
The present invention be the inventor from traditional Chinese medical science organic conception, under the thought guidance of determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, the technical scheme of the science practicality of summing up out by long-term practice.Prescription of the present invention is to show as the insufficient deficiency syndrome of healthy energy at immunologic hypofunction or not normal patient more; consolidate with reinforcing spleen and kidney, QI invigorating and to be the main rule of treatment; getting famous ancient prescription " YUPINGFENG SAN " and " decoction of four noble drugs " set upright adds and simplifies sanction; form by the Radix Astragali, Radix Codonopsis, Poria, the Rhizoma Atractylodis Macrocephalae, Fructus Ligustri Lucidi, Herba Epimedii; all medicines share, and QI invigorating is main, the nourishing YIN sun of holding concurrently; spleen benefiting and strengthen kidney, the lung benefiting nourishing the liver of holding concurrently.Full side is sweet light gentle, tonify without causing stagnation, taste and oiliness, and temperature and not dry, all suitable a little less than old and young woman.Its function of prescription of the present invention cures mainly and is reinforcing spleen and kidney, and QI invigorating consolidates.Can be used for weakness of the spleen and kidney, the fatigue and asthenia due to the positive QI-insufficiency, inappetence, soreness of the waist and knees, edema cough with asthma or chronic disease are low with cellular immunization, and the immunologic function disorder person has significant enhancing and regulating action to the low or disorder of immunologic function; Treatment deficiency of vital energy edema (chronic nephritis nephropathy type) effect is obvious.
We's dosage form has tablet, granule, pill, capsule, oral liquid.Title of the present invention can be stilbene Siberian cocklebur QI invigorating.
Further set forth the present invention below by embodiment, the present invention is not limited only to described embodiment.
The specific embodiment:
Embodiment one
Get 15 parts of the Radixs Astragali, 6 parts of Radix Codonopsis, 12 parts in Poria, 8 parts of the Rhizoma Atractylodis Macrocephalaes, above-mentioned primary crude drug mixture is decocted, each 100kg medical material adds the drinking water of 1000L approximately, boil after for the first time soaking 30min, decoct secondary, each 45~100 minutes, collect volatile oil simultaneously, get medicinal liquid; 200 mesh sieves filtration back concentrates with the triple effect concentrator, and one imitates 80 ℃ of temperature, two 70 ℃ of effects, 60 ℃ of triple effects, the clear paste of simmer down to relative density 1.08~1.18; Get the spray drying tower powder process of half clear paste, 160~180 ℃ of inlet temperature, 80~100 ℃ of leaving air temps get extract powder; Second half remaining clear paste and extract powder one-step palletizing airpillow-dry mechanism granule, 60~80 ℃ of inlet temperature, 45~70 ℃ of leaving air temps get granule, add above-mentioned volatile oil, mixing is made granule, be distributed into 5000 bags with the granule racking machine, every bag of 5g gets finished product.
Embodiment two
Get 18 parts of the Radixs Astragali, 8 parts of Radix Codonopsis, 15 parts in Poria, 10 parts of the Rhizoma Atractylodis Macrocephalaes, above-mentioned primary crude drug is mixed decocting, each 100kg medical material adds the drinking water of 1000L approximately, boil after for the first time soaking 30min, decoct secondary, each 45~100 minutes, collect volatile oil simultaneously, get medicinal liquid; 200 mesh sieves filtration back adds the triple effect concentrator and concentrates, and one imitates 80 ℃ of temperature, two 70 ℃ of effects, 60 ℃ of triple effects, is concentrated into the clear paste of relative density 1.08~1.18; Get the spray drying tower powder process of half clear paste, 160~180 ℃ of inlet temperature, 80~100 ℃ of leaving air temps get extract powder; Second half remaining clear paste and extract powder one-step palletizing airpillow-dry mechanism granule, 60~80 ℃ of inlet temperature, 45~70 ℃ of leaving air temps get granule; Add above-mentioned volatile oil and moderate lubrication agent or binding agent tabletting (0.48~0.52g/ sheet), reuse high-efficiency coating machine coating is distributed into 400 bottles, 120 every bottle, gets the tablet product.
Embodiment three
Get 12 parts of the Radixs Astragali, 5 parts of Radix Codonopsis, 7 parts in Poria, the Rhizoma Atractylodis Macrocephalae 5,6 parts of Fructus Ligustri Lucidi, 9 parts of steps of Herba Epimedii by embodiment one process grain products.
Embodiment four
Get 13 parts of 18 parts of the Radixs Astragali, 8 parts of Radix Codonopsis, 15 parts in Poria, the Rhizoma Atractylodis Macrocephalae 10,12 parts of Fructus Ligustri Lucidi, Herba Epimedii above-mentioned primary crude drug is ground into fine powder, sieve mixing, add refined honey and an amount of water and make soft material, use the pellet processing machine pill, cold drying, check gets the pill product.
Embodiment five
Get 16 parts of the Radixs Astragali, 6 parts of Radix Codonopsis, 14 parts in Poria, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 13 parts of Fructus Ligustri Lucidi, 10 parts of Herba Epimedii, by the step of embodiment one process granule, further filled capsules on capsule filler, inspect by ready samples, the capsule product.
Embodiment six
Get 15 parts of the Radix Astragali Radixs Astragali, 5 parts of Radix Codonopsis, 12 parts in Poria, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Fructus Ligustri Lucidi, 8 parts of Herba Epimedii, above-mentioned primary crude drug mixture is decocted, each 100kg medical material adds the drinking water of 1000L approximately, boil after for the first time soaking 40min, decoct secondary, each 45~100 minutes, collect volatile oil simultaneously, get medicinal liquid; Filter the back and be concentrated into every 1ml medicinal liquid with the energy-conservation concentrator of triple effect and be equivalent to crude drug 2g approximately, put coldly, add the remove impurity of ethanol precipitate with ethanol, stir evenly placement 24h.Filter, filtrate recycling ethanol does not extremely have the alcohol flavor, adds above-mentioned volatile oil, and with preparations such as an amount of water, syrup and adjuvants, embedding is in the control oral liquid bottle, and every bottle of 10ml with 100 ℃ of sterilization 30min, gets 5000 oral liquid finished products.
In addition, the Fructus Ligustri Lucidi in embodiment three to embodiment six raw materials, Herba Epimedii be in the two, also can only add wherein a kind of.
Further specify the beneficial effect of product of the present invention below by the clinical trial situation.
The II clinical trial phase situation of product of the present invention:
Product particle of the present invention is the health care medicine of treatment deficiency of vital energy edema (chronic nephritis, nephropathy type), participates in carrying out the II clinical trial phase by two tame hospitals of Shandong Tai'an City Hospital of Traditional Chinese Medicine.From year July in July, 1997-1999, observe deficiency of vital energy edema patient 240 examples altogether, wherein test group 180 people.Take product particle of the present invention; Matched group 60 people take " paecilomyces hepiall chen ".Observed result shows: test group total effective rate 86.11%, matched group total effective rate 88.33%.Two groups are not relatively had significant difference (P>0.05).Result of the test shows that product particle treatment deficiency of vital energy edema of the present invention (chronic nephritis nephropathy type) has better curative effect.
Research purpose
Objective evaluation product particle of the present invention treatment chronic nephritis nephropathy type Chinese medical discrimination belongs to the clinical efficacy of deficiency of vital energy edema and to the safety of human body.
Physical data
The case source
Test group 180 people and matched group 60 people, be the Supreme People's Court and the Supreme People's Procuratorate's outpatient service and inpatient, clinically be divided into two groups at random, all, be diagnosed as chronic nephritis nephropathy type, except that objective indicator through routine blood test, routine urinalysis, stool routine examination, blood fat, kidney function test, every patient's clinical manifestation all possesses three-hypers, and (that is: high protein is urinated, the height edema, the hypercholesterolemia blood disorder), one low (that is: hypoproteinemia card) feature.All do not have significant difference at sex, age, the course of disease, clinical symptoms and aspects such as picture of the tongue, pulse condition before two patient's cases source and the treatment, two groups of cases have comparability.See table 1-8 for details.
1 test case ordinary circumstance
Two groups of patients' case source and sex do not have significant difference, see Table 1.
Table 1 liang group case source, sex comparison sheet
| Group | n | Be in hospital | Outpatient service | The man | The woman | ||||
| n | % | n | % | n | % | n | % | ||
| The test group matched group | 180 60 | 115 41 | 63.89 68.33 | 65 19 | 36.11 31.67 | 96 42 | 53.33 70.00 | 84 18 | 46.67 30.00 |
Learn by statistics and handle: case source X
2=0.26 P>0.05
Sex ratio is than X
2=1.21 P>0.05
2 ages
Two groups of patient age do not have significant difference, see Table 2
Table 2 a liang group patient age distributes and the mean age comparison sheet
| Group | n | 16 years old- | 21 years old- | 31 years old- | 41 years old- | 51 years old- | X±S | |||||
| n | % | n | % | n | % | n | % | n | % | |||
| The test group matched group | 180 60 | 72 16 | 40.00 27.00 | 54 14 | 30.00 23.00 | 27 18 | 15.00 30.00 | 9 10 | 5.00 16.70 | 18 2 | 10.00 3.30 | 28.16±13.20 36.12±12.72 |
Learn by statistics and handle X
2=2.85 P>0.05.
3, two groups of courses of disease do not have significant difference, learn result X by statistics
2=0.015, P>0.05 (full edition omits, and is as follows).
4. two groups of preceding mild symptoms weight classifications of patient do not have significant difference, learn result X by statistics
2=1.42 P>0.05.
5, the tcm syndrome related symptoms does not relatively have significant difference, learns by statistics and handles, and the P value all>0.05.
6, two groups of case picture of the tongues relatively do not have significant difference, learn by statistics and handle: two groups of patients compare X from body of the tongue
2=0.78 P>0.05; Two groups of patients compare X from tongue fur
2=0.87P>0.05.
7, two groups of patient's pulse conditions relatively do not have significant difference, learn by statistics and handle X
2=0.82P>0.05.
8, two groups of preceding immune indexes of patient more all do not have significant difference, learn by statistics and handle, and the P value all>0.05.
Test method
One, case choice criteria
(1) diagnostic criteria:
1, Western medicine diagnose standard (standard that meeting was drafted with reference to second national nephropathy science in 1985)
(1) onset is slow, state of an illness delay, the time heavy when light, renal function progressively goes down, anemia can appear in the later stage, electrolyte disturbance, situations such as blood urea nitrogen, serum creatinine rising.
(2) in various degree performances such as albuminuria, hematuria, edema and hypertension are arranged.
(3) can bring out acute attack because of reasons such as respiratory tract infection in the course of disease, the performance of similar acute nephritis occur, also have some cases can have automatic alleviation to separate the phase.
(4) can further divide into according to clinical manifestation:
Plain edition: the various symptoms of nephritis are arranged, but do not have outstanding behaviours;
Hypertension type: except that general nephritis symptom, hypertensive outstanding behaviours is arranged;
Acute attack type: the performance of acute nephritis syndrome in chronic process, occurs.
2, Chinese medical discrimination (" the chronic primary glomerulopathy Chinese medical discrimination typing tentative program " that pass through with reference to second national traditional Chinese medical science nephropathy Symposium in 1986)
(1) assertive evidence; Syndrome of qi deficiency of lung and kidney
In following 5 pattern of syndrome, all possess wherein any 3 persons, can be diagnosed as this card.
A, edema, shallow complexion; B, weak breath are unable; , easily catch a cold; D, ache of the spinal column; E, light red tongue, white and moist fur have the tooth seal, thready and weak pulse.
(2) standard card: water is wet, the turbid damp card.All possess following any 1 person, can determine.
A, indigestion and loss of appetite, n or V; B, heavy sensation of the body is sleepy or listlessness; C, the above edema of whole body moderate or hydrothorax, ascites; D, blood urea nitrogen, creatinine are higher.
3, chronic nephritis weight grade scale
The weight of the state of an illness mainly judges from aspects such as albuminuria, renal function, edema, hypertension, syndrome of blood stasis, and all possess following any 1 and can determine.
(1) severe
A, urine protein examination continue ++ +~++ ++, or the twenty-four-hour urine protein quantification is between 2.1~3.5g, serum albumin>30g/L; B, renal function undesired (serum creatinine 〉=442 μ mol/L persons are not therein); C, obvious edema and hypertension; D, the performance of obvious syndrome of blood stasis is arranged.
(2) moderate
A, urine protein examination continue ++~+++, or the twenty-four-hour urine protein quantification continues between 1~2g, and renal function is normal: B, edema can gently can weigh, and hypertension can be arranged; C, the clinical manifestation of slight syndrome of blood stasis is arranged.
(3) slight
A, urine protein examination continue +~++, or the twenty-four-hour urine protein quantification continues below 1g, and renal function is normal; B, edema are not obvious, and blood pressure is normal; C, there is or do not have the syndrome of blood stasis clinical manifestation.
(4) Syndrome in TCM shape weight grade scale: see Table 3.
(2) test case standard
1, includes disease row standard in
The chronic nephritis patient of all serum creatinine<5mg/dl (442 μ mol/L), and the person that meets the Chinese medical discrimination can include the test case in.
(3) test case quantity and group technology
1, test group 180 examples, matched group 60 examples adopt inpatient and clinic case, and wherein inpatient is no less than 60% of total routine number, and clinic case selects compliance good, the case of may command variable factor.
2, patient was divided into two groups at random by 3: 1, one group is test group totally 180 examples, and another group is matched group totally 60 examples.
Table 3 tcm symptom weight grade scale
| Tcm symptom | Gently (+) | In (++) | Heavy (+++) |
| Puffiness of the face and limbs | The depression that face and time body Mild edema are pressed is easily recovered | Edema is obvious, and the depression of more so pressing below the waist is difficult for recovering | The above hydrosarca of moderate is stayed for a long time and is not moved back, by depression be difficult to recover |
| Short breath | Breathe hard after the activity | Move slightly and promptly breathe hard | Also breathe hard usually |
| Spiritlessness and weakness | Lassitude can be supported physical work | Spirit is tired, adheres to routine work reluctantly | Spirit is extremely tired, can not support daily work |
| Ache of the spinal column | Idol has outbreak | Outbreak repeatedly | Continue outbreak, be difficult for alleviating |
| Poor appetite abdominal distention | Appetite is poor, appetite does not subtract, and slight abdominal distention disappears in 0.5 hour or alleviates | No appetite, appetite reduces in 1/2, abdominal distention more very continues 0.5-2 hour | No appetite, appetite descends more than 1/2, and serious abdominal distention continues more than 2 hours |
| Light red tongue or tooth seal is arranged | |||
| Control white and moist or white being bored with | |||
| Deep-slow pulse or thin and delicate |
Indicate: by light (+), in (++), heavy (+++) be designated as 1,2,3 fen respectively; Tongue, arteries and veins are with "+", "-" expression.
Two, Therapeutic Method
(1) treatment group: product of the present invention, every day 3 times, obey 3 grams at every turn.
(2) matched group: " paecilomyces hepiall chen ", every day 3 times, each 3.
(3) course of treatment:, serve on three courses of treatment all around.
(4) inactive any medicine relevant and Therapeutic Method before the treatment with primary disease.
Three, observation index
(1) safety observation:
A, general health check-up project: B, blood, urine, just routine test; C, the heart, liver, kidney function test.
(2) health giving quality observation:
1, symptom: puffiness of the face and limbs, weak breath is weak, ache of the spinal column, poor appetite abdominal distention etc. with gently+, in ++, heavy +++expression.
2, sign: shallow complexion, puffiness of the face and limbs by depression do not rise, have or not breast, ascites, the position of edema and degree etc. with gently+, in ++, heavy +++expression.
Tongue fur: white and moist, thin, thick etc.; Body of the tongue: light, red, dark etc.; Tongue shape: there is tooth seal on the limit, and is fat tender etc.; Pulse condition: thin, weak, heavy slow etc.
3, twenty-four-hour urine protein quantification, routine urinalysis and uropsammus examination;
Routine urinalysis is checked weekly once;
Urine sediments analyzer and twenty-four-hour urine protein quantification were checked, and were write down 1 time in every month;
Routine urianlysis is observed albumen, cast, erythrocyte and record.
4, immune indexes inspection: adopt single-phase agar diffusion method to measure periphery serum, immunoglobulin IgG, lgA, lgM and complement C before and after the treatment
3Content value and record.Normally: data return to normal range, see Table 9,
5, kidney function test comprises serum creatinine, blood urea nitrogen etc.
6, blood fat: lipid examination comprises cholesterol, triglyceride determination.
Table 9 immune indexes normal value table
| IgG | lgA | lgM | C 3 |
| 11.2±3.2g/L | 1.7±0.56g/L | 1.35±0.59g/L | 0.5-1.5g/L |
Four, curative effect determinate standard
(1) symptom curative effect determinate standard:
1, alleviation fully: symptom and sign complete obiterations such as edema, the lasting feminine gender of urine protein examination or " ± " are more than 2 months, or the twenty-four-hour urine protein quantification is lasting less than 0.2g, and urine erythrocyte disappears under the high power lens, and Urine sediments analyzer is counted normally, and renal function is normal.
2, produce effects; Symptom such as edema and sign disappear substantially, and the urine protein examination continuous decrease is more than 50%, and urine erythrocyte is no more than 3 under the high power lens, and the Urine sediments analyzer counting is near normal, and renal function normally or normal substantially (differ be no more than 15% with normal value).
3, effective: symptom such as edema and sign are clearly better 1 of urine protein examination continuous decrease "+"; Or twenty-four-hour urine protein quantification continuous decrease 25-49%, urine erythrocyte is no more than 5 under the high power lens, and renal function is normal or improvement arranged.
4, invalid: clinical manifestation and above-mentioned lab testing all do not have obvious improvement or the anti-person of increasing the weight of.
(2) tcm syndrome total effects criterion:
Formulate the traditional Chinese medical science according to integration method and wait total effects
Produce effects: n 〉=70%
Effectively: 70%>n 〉=30%
Invalid: n<30%
Result of the test
One, efficacy assessment standard:
Efficacy assessment standard mainly is that immune indexes is answered Chang Chengdu and formulated according to tcm syndrome curative effect, sign improvement, three-hypers one low characteristic change.
1, symptom general curative effect:
Two groups of whole curative effects compare: test group total effective rate 86.11%, and matched group total effective rate 88.33%, no significant difference, P>0.05 sees Table 4.
Table 4 liang group patient symptom total effects comparison sheet
| Group | n | Produce effects | Effectively | Invalid | Total effective rate % | P | |||
| n | % | n | % | n | % | ||||
| The test group matched group | 180 60 | 138 45 | 76.67 75.00 | 17 8 | 9.40 13.33 | 25 7 | 13.89 11.67 | 86.11 88.33 | P>0.05 |
Learn by statistics and handle: the symptom total effects is X relatively
2=1.23 P>0.05
2, tcm symptom curative effect: the tcm symptom curative effect compares, and two groups of cases self are relatively treated each individual event symptom integral of back all than the preceding obviously decline of treatment, significant difference, and (P<0.01) sees Table 5.
Comparison sheet before and after the table 5 liang group tcm symptom integration treatment
| Project | n | Test group (180 example) | n | Matched group (60 example) | ||||
| X±S | t | P | X±S | t | P | |||
| The swollen spiritlessness and weakness of the floating glue of ache of the spinal column face is breathed to breathe hard and is received poor abdominal distension | 180 180 159 138 160 | Behind front 19.78 ± 0.69 medicines of medicine behind front 18.01 ± 0.17 medicines of 10.87 ± 0.28 medicines behind front 19.21 ± 0.38 medicines of 11.89 ± 0.90 medicines behind front 18.49 ± 0.85 medicines of 10.87 ± 0.28 medicines behind front 16.29 ± 0.71 medicines of 10.86 ± 0.60 medicines 10.89 ± 0.69 | 10.81 12.91 10.81 16.21 10.82 | <0.01 <0.01 <0.01 <0.01 <0.01 | 40 60 60 50 28 | Behind front 19.21 ± 0.73 medicines of medicine behind front 17.16 ± 0.29 medicines of 10.97 ± 0.92 medicines behind front 18.17 ± 0.72 medicines of 12.01 ± 0.90 medicines behind front 18.56 ± 1.01 medicines of 11.48 ± 0.93 medicines behind front 16.72 ± 0.97 medicines of 10.92 ± 0.69 medicines 10.78 ± 0.79 | 7.45 12.01 8.99 8.01 6.02 | <0.01 <0.01 <0.01 <0.01 <0.01 |
3, the tongue arteries and veins improves situation
(1) the improvement situation of picture of the tongue:
Picture of the tongue improvement situation according to two groups of patients compares, no big variation before and after the treatment, but obvious with the fat improvement of pale tongue.See Table 6.
The table 6 liang unusual picture of the tongue situation of group
| Test group (180 example) | Matched group (60 example) | |||||||
| Pale tongue is fat | Tongue is greasy in vain | Pale tongue is fat | Tongue is greasy in vain | |||||
| n | % | n | % | n | % | n | % | |
| After treating before the treatment | 138 127 | 76.67 70.56 | 129 112 | 71.67 62.22 | 40 32 | 66.67 53.33 | 41 36 | 68.33 60.00 |
(2) the improvement situation of pulse condition:
Two groups of patients' pulse condition changes with thready and weak pulse and improves obviously, sees Table 7.
The table 7 liang unusual pulse condition situation of group
| Test group (180 example) | Matched group (60 example) | |||||||||||
| Late heavy | Thin and delicate | Other | Late heavy | Thin and delicate | Other | |||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| After treating before treating | 65 62 | 36.11 34.44 | 72 35 | 40.00 19.44 | 43 38 | 23.89 21.11 | 23 16 | 38.33 26.67 | 20 12 | 33.33 20.00 | 17 13 | 28.33 21.67 |
4, immune curative effect:
The immunity total effects compares: test group normalization rate 53.33%, 48.33%, two group of significant difference of matched group normalization rate (P<0.05).Test group total effective rate 91.10%.The matched group total effective rate does not relatively have significant difference for 90.00%, two group, and (P<0.05) sees Table 8.
The table 8 a liang group immune total effects comparison sheet in 30 table backs of taking medicine
| Group | n | Multiple normal | Effectively | Invalid | Total effective rate % | P | |||
| n | % | n | % | n | % | ||||
| The test group matched group | 180 60 | 96 29 | 53.33 48.33 | 68 25 | 37.78 41.67 | 16 6 | 8.89 10.00 | 91.10 90.00 | >0.05 |
Discuss
1, edema is disease, YIN edema is arranged, the branch of YANG edema, observe case and select the YIN edema case, onset is slow, disease deeply with the passing of time, edema with the edema below the waist very, by depression do not rise, dysuria, spinal column are aching and limp, spiritlessness and weakness, easy to catch cold, poor appetite abdominal distention, pale tongue with thin fur are white, deep,thready and forceless pulse, dialectically be the insufficiency of QI of the lung and kidney edema.
2, product of the present invention has the function of kidney and spleen invigorating, inducing diuresis to remove edema preferably, for the spleen deficiency of kidney-QI, and the imbalance of water liquid metabolic function, the water hydrorrhea improves significantly in the edema that skin forms.
3, two groups of patient's primary conditions: age, sex, the course of disease, the balanced equity of severity extent have comparability.
4, observed result shows: product of the present invention is apparent in view to the improvement of deficiency of vital energy symptom, and the average product score value descends 8.08%; Paecilomyces hepiall chen component value descends 6.78.Test group total effective rate 86.11%, matched group total effective rate 88.33%, (P>0.05), two groups of curative effects relatively do not have significant difference.
5, to the improvement of immunologic function, test group normalization rate 53.33%, matched group normalization rate 48.33%, (P<0.05); Therefore this medicine is to regulating body's immunity, and the resistance against diseases of enhancing body is got well, and therapeutical effect is preferably arranged.
6, all do not find any untoward reaction in the observation.
Conclusion
Product treatment chronic nephritis nephropathy type Chinese medical discrimination of the present invention belongs to deficiency of vital energy edema person, and clinical efficacy is definite, no obvious toxic-side effects.
Claims (2)
1. treat immunologic hypofunction or disorderly Chinese medicine for one kind, it is characterized in that it is a raw material by following weight portion: Radix Astragali 10-20 part, Radix Codonopsis 3-9 part, Poria 6-18 part, Rhizoma Atractylodis Macrocephalae 4-12 part, through being processed into tablet, granule, pill, capsule or oral liquid.
2. treatment immunologic hypofunction according to claim 1 or disorderly Chinese medicine is characterized in that can also adding in the described raw material Fructus Ligustri Lucidi 5-15 part and/or Herba Epimedii 8-16 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135227 CN1228074C (en) | 2003-06-18 | 2003-06-18 | Chinese traditional medicine for treating immune hypofunction and disfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135227 CN1228074C (en) | 2003-06-18 | 2003-06-18 | Chinese traditional medicine for treating immune hypofunction and disfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1565552A CN1565552A (en) | 2005-01-19 |
| CN1228074C true CN1228074C (en) | 2005-11-23 |
Family
ID=34470226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03135227 Expired - Fee Related CN1228074C (en) | 2003-06-18 | 2003-06-18 | Chinese traditional medicine for treating immune hypofunction and disfunction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1228074C (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716330A (en) * | 2012-06-25 | 2012-10-10 | 李良 | Astragalus traditional Chinese medicine decoction for treating edema and preparation method thereof |
| CN103860656A (en) * | 2012-12-11 | 2014-06-18 | 洛阳惠中兽药有限公司 | Traditional Chinese medicinal composition, and preparation method and application thereof |
| CN103230468A (en) * | 2013-04-28 | 2013-08-07 | 苏州谷力生物科技有限公司 | Traditional Chinese medicine composition with functions of tonifying spleens and nourishing stomachs and preparation method thereof |
| CN103621706B (en) * | 2013-12-03 | 2015-04-22 | 高子建 | Traditional Chinese medicine health tea and manufacturing method |
| CN104800293A (en) * | 2015-05-14 | 2015-07-29 | 胡少平 | Veterinary codonopsis pilosula and astragalus immunity improving Chinese medicine preparation |
| CN104888158A (en) * | 2015-07-07 | 2015-09-09 | 青岛恒波仪器有限公司 | Folium apocyni veneti oral liquid for enhancing immunity and preparation method thereof |
| CN105076613A (en) * | 2015-09-02 | 2015-11-25 | 淮安市中医院 | Health-care teabag containing astragalus membranaceus and largehead atractylodes rhizome and preparation method of health-care teabag |
| CN106728413A (en) * | 2016-12-30 | 2017-05-31 | 广西山水牛农业有限责任公司 | A kind of Chinese medicine composition and preparation method for improving severe ox immunity |
| CN107158237A (en) * | 2017-06-05 | 2017-09-15 | 中国农业科学院特产研究所 | A kind of raising immunity, antifatigue Chinese medicine composition, join the preparation method of chankings |
| CN107261053A (en) * | 2017-08-14 | 2017-10-20 | 龙岩学院 | Ginkgo leaf compound immunoenhancer |
| CN107961272B (en) * | 2017-12-22 | 2021-04-16 | 上海交通大学医学院附属仁济医院 | A kind of traditional Chinese medicine composition for chronic kidney disease |
| CN108159285A (en) * | 2018-02-09 | 2018-06-15 | 恒康宝健康科技(北京)有限公司 | A kind of Chinese medicine composition of strengthen immunity and preparation method thereof |
| CN110478392A (en) * | 2019-08-02 | 2019-11-22 | 江苏康缘药业股份有限公司 | A kind of composition and preparation method thereof with strengthen immunity function |
| CN111375010A (en) * | 2020-03-19 | 2020-07-07 | 兰州大学第一医院 | A traditional Chinese medicine composition with the functions of strengthening the body and strengthening the body, invigorating the liver and kidney, and enhancing immunity |
| CN113663014A (en) * | 2021-09-17 | 2021-11-19 | 黑龙江省蟾宝生物科技发展有限公司 | Preparation method of toad feeding particles for lung cancer |
| CN116421669A (en) * | 2023-04-20 | 2023-07-14 | 四川轻化工大学 | Vinegar egg traditional Chinese medicine oral liquid and preparation method and application thereof |
| CN117244016A (en) * | 2023-10-25 | 2023-12-19 | 广州中医药大学第一附属医院 | A traditional Chinese medicine composition for preventing and treating cancer-related fatigue and its preparation method |
| CN117379481B (en) * | 2023-11-28 | 2025-11-11 | 中国中医科学院广安门医院 | Traditional Chinese medicine composition for preventing or/and treating type 2 heart kidney syndrome and application thereof |
-
2003
- 2003-06-18 CN CN 03135227 patent/CN1228074C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1565552A (en) | 2005-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN100341555C (en) | Traditional Chinese medicine for conditioning the body and nourishing the body | |
| CN1943761A (en) | A Medicine for treatment of ascites due to cirrhosis | |
| CN1232285C (en) | Chinese Medicine for treating cervieal vertebra disease and its preparation method | |
| CN102631595A (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN1682936A (en) | A kind of pharmaceutical composition for treating hyperlipidemia and preparation method thereof | |
| CN102526611A (en) | Chinese medicinal composition for treating chronic heart failure | |
| CN1289115C (en) | A kind of traditional Chinese medicine for improving immunity and preparation method thereof | |
| CN1261138C (en) | Medicine for increasing immunocompetence of children and its preparing process | |
| CN1301129C (en) | A medicine for treating wind-cold-damp arthralgia and weakness of muscles and bones | |
| CN105079532A (en) | Healthcare green tea capable of reducing blood fat and loosing weight and preparation method of healthcare green tea | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1190206C (en) | Traditional Chinese medicine Shenkang pill and its production method | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1161132C (en) | Tibetan medicine for treating liver diseases and preparation method thereof | |
| CN1234407C (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN100344304C (en) | Traditional Chinese medicine preparation for treating consumptive disease and preparation method thereof | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process | |
| CN1211110C (en) | Chinese medicine composition for treating tumour | |
| CN1120011C (en) | Chinese herb medicine composition for treating glomerulonephritis | |
| CN1076622C (en) | Chinese medicine for curing nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051123 Termination date: 20120618 |